S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
Log in

NASDAQ:ALKS - Alkermes Stock Price, Forecast & News

$18.67
+1.06 (+6.02 %)
(As of 02/19/2020 04:00 PM ET)
Today's Range
$17.54
Now: $18.67
$18.82
50-Day Range
$17.15
MA: $18.73
$20.40
52-Week Range
$16.65
Now: $18.67
$37.75
Volume2.46 million shs
Average Volume1.59 million shs
Market Capitalization$2.95 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.97
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALKS
CUSIPG0176710
Phone353-1772-8000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.17 billion
Cash Flow$0.61 per share
Book Value$6.88 per share

Profitability

Net Income$-196,620,000.00

Miscellaneous

Employees2,300
Market Cap$2.95 billion
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.


Alkermes (NASDAQ:ALKS) Frequently Asked Questions

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

How were Alkermes' earnings last quarter?

Alkermes Plc (NASDAQ:ALKS) announced its earnings results on Thursday, February, 13th. The company reported $0.83 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.65 by $0.18. The business had revenue of $412.70 million for the quarter, compared to the consensus estimate of $404.45 million. Alkermes had a negative net margin of 16.79% and a positive return on equity of 1.58%. The business's revenue for the quarter was up 30.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.34 earnings per share. View Alkermes' Earnings History.

When is Alkermes' next earnings date?

Alkermes is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for Alkermes.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes updated its FY20 earnings guidance on Thursday, February, 13th. The company provided earnings per share guidance of $0.25 to $0.43 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.52. The company issued revenue guidance of $1.03 billion to $1.08 billion, compared to the consensus revenue estimate of $1.06 billion.

What price target have analysts set for ALKS?

11 brokerages have issued 1-year price targets for Alkermes' stock. Their forecasts range from $19.00 to $28.00. On average, they anticipate Alkermes' stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 23.2% from the stock's current price. View Analyst Price Targets for Alkermes.

What is the consensus analysts' recommendation for Alkermes?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 9 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alkermes.

What are Wall Street analysts saying about Alkermes stock?

Here are some recent quotes from research analysts about Alkermes stock:
  • 1. According to Zacks Investment Research, "Alkermes reported impressive third-quarter results wherein both earnings and sales beat estimates. With increasing traction of Aristada in the market, Alkermes is emerging as a leader in the treatment of schizophrenia. This year will be an important one for the company’s late-stage pipeline owing to the planned submission of the NDA for ALKS 3831 for both schizophrenia and bipolar I disorder indications. The company also expects action on the regulatory review of the recently submitted NDA for Vumerity (diroximel fumarate) for multiple sclerosis in the fourth quarter. However, Alkermes is highly dependent on manufacturing and/or royalty revenues from partners, which is a concern. Shares have underperformed the industry year to date." (1/2/2020)
  • 2. HC Wainwright analysts commented, "Valuation Our $28 price target for Alkermes is based on our sum-of-the-parts NPV valuation based on each of the company’s marketed products and pipeline assets. Our DCF model utilizes a discount rate of 13.1% based on the company’s WACC (Beta of 1.9, equity risk premium of 6.7%)." (5/31/2019)

Has Alkermes been receiving favorable news coverage?

News articles about ALKS stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alkermes earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Alkermes.

Are investors shorting Alkermes?

Alkermes saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 5,250,000 shares, an increase of 10.5% from the December 31st total of 4,750,000 shares. Based on an average daily volume of 1,570,000 shares, the short-interest ratio is currently 3.3 days. Currently, 3.4% of the company's stock are short sold. View Alkermes' Current Options Chain.

Who are some of Alkermes' key competitors?

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include AbbVie (ABBV), Netflix (NFLX), Celgene (CELG), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Starbucks (SBUX), Pfizer (PFE) and Advanced Micro Devices (AMD).

Who are Alkermes' key executives?

Alkermes' management team includes the folowing people:
  • Mr. Richard F. Pops, Chairman & CEO (Age 57)
  • Dr. Floyd E. Bloom, Co-Founder & Director (Age 82)
  • Mr. James M. Frates, Sr. VP & CFO (Age 52)
  • Mr. David Joseph Gaffin, Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 47)
  • Dr. Craig C. Hopkinson, Sr. VP of Medicines Devel. & Medical Affairs and Chief Medical Officer (Age 51)

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.21%), State Street Corp (2.95%), FMR LLC (1.78%), First Trust Advisors LP (1.78%), AQR Capital Management LLC (1.22%) and Goldman Sachs Group Inc. (0.98%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Floyd E Bloom, James M Frates, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops. View Institutional Ownership Trends for Alkermes.

Which institutional investors are selling Alkermes stock?

ALKS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Asset Management Americas Inc., State Street Corp, Korea Investment CORP, UBS Group AG, Swiss National Bank, AQR Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have sold Alkermes company stock in the last year include David Joseph Gaffin, Michael J Landine, Paul J Mitchell and Richard F Pops. View Insider Buying and Selling for Alkermes.

Which institutional investors are buying Alkermes stock?

ALKS stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Krensavage Asset Management LLC, Goldman Sachs Group Inc., Russell Investments Group Ltd., Jacobs Levy Equity Management Inc., Connor Clark & Lunn Investment Management Ltd., Bank of Montreal Can and First Trust Advisors LP. View Insider Buying and Selling for Alkermes.

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $18.67.

How big of a company is Alkermes?

Alkermes has a market capitalization of $2.95 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,300 workers across the globe.View Additional Information About Alkermes.

What is Alkermes' official website?

The official website for Alkermes is http://www.alkermes.com/.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]


MarketBeat Community Rating for Alkermes (NASDAQ ALKS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  608 (Vote Outperform)
Underperform Votes:  451 (Vote Underperform)
Total Votes:  1,059
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe ALKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel